Trump signs order raising Canada tariffs to 35% from 25%
John Rondoni, the Chief Technology Officer of Inspire Medical (TASE:PMCN) Systems, Inc. (NYSE:INSP), recently executed a stock sale as part of a pre-established trading plan. On February 11, Rondoni sold 583 shares of the company’s common stock at an average price of $170.49 per share, totaling approximately $99,395. This transaction was conducted under a Rule 10b5-1 trading plan initiated on May 23, 2024.
Prior to this, on February 9, Rondoni disposed of 315 shares at $182.15 each to cover tax obligations related to the vesting of restricted stock units. Following these transactions, Rondoni holds 10,424 shares of Inspire Medical Systems directly. The company has demonstrated strong historical performance, with InvestingPro data showing robust returns over both five and ten-year periods. Discover 13 additional key insights about INSP with an InvestingPro subscription.
In other recent news, Inspire Medical Systems has been the subject of various analyst evaluations following its fourth-quarter results for the year 2024. UBS has maintained a Buy rating on the company's stock, with a target of $265, citing the company's continued growth and potential to sustain adoption momentum, despite an ongoing Department of Justice investigation. Similarly, RBC Capital Markets has kept an Outperform rating with a steady price target of $260, noting a solid beat on earnings per share (EPS) and revenue that aligned with expectations.
Truist Securities adjusted its price target for Inspire Medical Systems to $235, while maintaining a Buy rating, acknowledging the company's solid gross margin and EPS beat, as well as its EPS guidance for the year 2025 that exceeded expectations. Meanwhile, Morgan Stanley (NYSE:MS) reduced its price target from $230 to $220, continuing to endorse the stock with an Overweight rating, suggesting there might be room for positive performance despite the Central Initiator Device issue.
Lastly, Piper Sandler reiterated an Overweight rating on Inspire Medical Systems with a $233 price target, highlighting the strength in the company's profit and loss leverage. These recent developments reflect a generally positive outlook on Inspire Medical Systems' performance and prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.